Zoetis (ZTS) Competitors $153.53 +2.34 (+1.55%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ZTS vs. IDXX, MRK, PFE, BMY, RPRX, CORT, JAZZ, PRGO, SUPN, and PCRXShould you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include IDEXX Laboratories (IDXX), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), and Pacira BioSciences (PCRX). These companies are all part of the "medical" sector. Zoetis vs. Its Competitors IDEXX Laboratories Merck & Co., Inc. Pfizer Bristol Myers Squibb Royalty Pharma Corcept Therapeutics Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Zoetis (NYSE:ZTS) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Which has more volatility & risk, ZTS or IDXX? Zoetis has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Does the media prefer ZTS or IDXX? In the previous week, Zoetis had 32 more articles in the media than IDEXX Laboratories. MarketBeat recorded 58 mentions for Zoetis and 26 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.45 beat Zoetis' score of 1.12 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 37 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive IDEXX Laboratories 20 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ZTS or IDXX? Zoetis presently has a consensus price target of $204.63, indicating a potential upside of 33.28%. IDEXX Laboratories has a consensus price target of $560.33, indicating a potential upside of 3.62%. Given Zoetis' higher probable upside, research analysts plainly believe Zoetis is more favorable than IDEXX Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zoetis 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.70IDEXX Laboratories 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has stronger earnings & valuation, ZTS or IDXX? Zoetis has higher revenue and earnings than IDEXX Laboratories. Zoetis is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZoetis$9.26B7.38$2.49B$5.5727.56IDEXX Laboratories$3.90B11.16$887.87M$10.8249.98 Is ZTS or IDXX more profitable? Zoetis has a net margin of 27.12% compared to IDEXX Laboratories' net margin of 22.76%. IDEXX Laboratories' return on equity of 57.35% beat Zoetis' return on equity.Company Net Margins Return on Equity Return on Assets Zoetis27.12% 55.48% 19.14% IDEXX Laboratories 22.76%57.35%26.97% Do institutionals and insiders have more ownership in ZTS or IDXX? 92.8% of Zoetis shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 1.0% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryIDEXX Laboratories beats Zoetis on 10 of the 16 factors compared between the two stocks. Get Zoetis News Delivered to You Automatically Sign up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZTS vs. The Competition Export to ExcelMetricZoetisMED IndustryMedical SectorNYSE ExchangeMarket Cap$68.33B$2.50B$5.66B$21.05BDividend Yield1.36%1.80%4.01%3.64%P/E Ratio27.559.1428.0727.93Price / Sales7.38601.79417.5169.82Price / Cash20.84165.2635.9622.19Price / Book14.535.178.554.71Net Income$2.49B$30.99M$3.24B$993.85M7 Day Performance1.37%4.88%4.86%2.93%1 Month Performance-2.53%16.58%13.00%6.75%1 Year Performance-14.41%0.23%35.57%11.39% Zoetis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZTSZoetis4.9669 of 5 stars$153.53+1.5%$204.63+33.3%-16.4%$68.33B$9.26B27.5513,800Positive NewsAnalyst RevisionIDXXIDEXX Laboratories3.6162 of 5 stars$531.74-0.3%$558.11+5.0%+11.9%$42.76B$3.93B49.1411,000Positive NewsMRKMerck & Co., Inc.4.9969 of 5 stars$83.72+0.4%$108.69+29.8%-35.0%$210.21B$64.17B12.1975,000Positive NewsUpcoming EarningsDividend AnnouncementAnalyst RevisionPFEPfizer4.98 of 5 stars$25.36-1.2%$28.55+12.6%-15.1%$144.15B$62.46B18.3781,000Positive NewsBMYBristol Myers Squibb4.7575 of 5 stars$47.36+1.1%$57.69+21.8%+12.5%$96.38B$47.64B17.7434,100RPRXRoyalty Pharma4.9708 of 5 stars$36.26+1.2%$48.33+33.3%+26.8%$20.39B$2.26B19.6080Positive NewsDividend AnnouncementAnalyst ForecastCORTCorcept Therapeutics4.8593 of 5 stars$72.78+1.2%$138.25+90.0%+99.8%$7.72B$675.04M62.74300News CoverageInsider TradeJAZZJazz Pharmaceuticals4.8854 of 5 stars$111.47+1.1%$184.00+65.1%+6.1%$6.75B$4.06B14.862,800Upcoming EarningsAnalyst ForecastPRGOPerrigo4.6678 of 5 stars$27.42-0.4%$33.00+20.4%-0.7%$3.77B$4.37B-20.938,379Positive NewsSUPNSupernus Pharmaceuticals1.6977 of 5 stars$33.95+2.5%$36.00+6.0%+8.9%$1.90B$661.82M30.59580News CoverageAnalyst DowngradePCRXPacira BioSciences3.1263 of 5 stars$23.33+1.9%$26.44+13.3%+11.0%$1.08B$700.97M-10.23720News CoverageUpcoming EarningsAnalyst Revision Related Companies and Tools Related Companies IDEXX Laboratories Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol Myers Squibb Alternatives Royalty Pharma Alternatives Corcept Therapeutics Alternatives Jazz Pharmaceuticals Alternatives Perrigo Alternatives Supernus Pharmaceuticals Alternatives Pacira BioSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZTS) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zoetis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zoetis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
